# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001437749-16-038450
Filing Date
2016-09-08
Accepted
2016-09-07 18:15:45
Documents
5
Period of Report
2016-06-17
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | FORM 8-K | atrn20160907_8k.htm | 8-K | 27181
2 | EXHIBIT 99.1 | ex99-1.htm | EX-99.1 | 2060
3 |  | a3.jpg | GRAPHIC | 336546
4 |  | a2.jpg | GRAPHIC | 229991
5 |  | a1.jpg | GRAPHIC | 235361
| Complete submission text file | 0001437749-16-038450.txt |  | 1135120

Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51353 | Film No.: 161874423
SIC: 7389 Services-Business Services, NEC